Skip to main content

CORRECTION article

Front. Mol. Neurosci., 22 December 2016
Sec. Methods and Model Organisms
Volume 9 - 2016 | https://doi.org/10.3389/fnmol.2016.00154
This article is part of the Research Topic Gene Therapy for the Central and Peripheral Nervous System View all 19 articles

Corrigendum: Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B

This article is a correction to:

  1. Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B

    1. Read original article
\r\nKasey L. JacksonKasey L. Jackson1Robert D. DaytonRobert D. Dayton1Benjamin E. DevermanBenjamin E. Deverman2Ronald L. Klein*Ronald L. Klein1*
  • 1Department of Pharmacology, Toxicology, and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, USA
  • 2Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA

A corrigendum on
Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B

by Jackson, K. L., Dayton, R. D., Deverman, B. E., Klein, R. L. (2016). Front. Mol. Neurosci. 9:116. doi: 10.3389/fnmol.2016.00116

The following acknowledgments were missing from the original article.

BD was supported by the Hereditary Disease Foundation, the Beckman Institute and the Resource Center for CLARITY, Optogenetics and Vector Engineering, which supports technology development and dissemination at the California Institute of Technology. The AAV-PHP.B plasmid was distributed from the Gradinaru Laboratory at the California Institute of Technology. The authors thank Viviana Gradinaru for her help in providing the AAV-PHP.B plasmid.

The authors apologize for this mistake. This error does not in any way change the scientific conclusions of the article.

Conflict of Interest Statement

BED is listed as an inventor on a patent application related to AAV-PHP.B. KLJ, RDD and RLK have no conflicts of interest to disclose.

Keywords: adeno-associated virus, amyotrophic lateral sclerosis, gene therapy, gene transfer, promoter, synapsin promoter, targeting, TDP-43

Citation: Jackson KL, Dayton RD, Deverman BE and Klein RL (2016) Corrigendum: Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B. Front. Mol. Neurosci. 9:154. doi: 10.3389/fnmol.2016.00154

Received: 29 November 2016; Accepted: 07 December 2016;
Published: 22 December 2016.

Edited and reviewed by: Andrew Paul Tosolini, University College London, UK

Copyright © 2016 Jackson, Dayton, Deverman and Klein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ronald L. Klein, a2xlaW5AbHN1aHNjLmVkdQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.